Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on December 3, 2018. The report covers a specific event occurring on the same date: the presentation of updated clinical data at the 60th American Society of Hematology (ASH) Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the presentation of updated data from an ongoing Phase 1b/2 study evaluating Onvansertib in combination with standard-of-care chemotherapy for Acute Myeloid Leukemia (AML). No financial changes or prior period comparisons are included in this document.
Outlook, Risks, and Management Commentary
Management highlighted the dissemination of clinical trial results via a poster presentation at a major industry conference. The filing does not contain specific forward-looking guidance, risk factors, or commentary on unusual items beyond the clinical update.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for specific clinical data details regarding Onvansertib.
- Confirm the status of the Phase 1b/2 study for Acute Myeloid Leukemia.
- Note that no financial data is available in this specific filing.